Search Results
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry
More news about: Innovent Biologics
May 31, 2026, 11:00 ET United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
12:30 p.m. This session features a series of lectures from international experts. Soma Somanesan, Ph.D. of Singapore General Hospital, Frank M. Bengel, MD of Hannover, Germany and Ciprian Catana, M.D., Ph.D. of Massachusetts General Hospital will share insights related to the uMI Panorama GS. The session
More news about: United Imaging Healthcare Co., Ltd.
May 31, 2026, 08:00 ET GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
advances and spreads. Earlier detection can open the door to more treatment options at any stage and increase the chance for cure," said Josh Ofman, MD, MSHS, President and CEO-Elect at GRAIL. "These PATHFINDER 2 results add to the growing body of clinical evidence in a large, representative intended-use
More news about: GRAIL, Inc.
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
neuroendocrine malignancies. In SCLC, it has levels of expression that are consistently high across disease stages and metastatic settings," said Afshin Dowlati, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University. "The magnitude of SEZ6 expression relative to other therapeutic targets,
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 14:30 ET Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
follow-upUS FDA granted seven-year period of orphan drug market exclusivity to PAPZIMEOSGERMANTOWN, Md., May 30, 2026 /PRNewswire/ --
More news about: Precigen, Inc.
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
mama metastásico alterado por la vía PI3K ER+/HER2-, en particular cuando hay mutaciones coexistentes en ESR1 y PIK3CA", señaló Sara Tolaney, MD, MPH, jefa de la División de Oncología de Mama del Instituto de Cáncer Dana-Farber. "Estos datos preliminares alentadores sugieren el posible beneficio
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
ROADS data?The multicenter ROADS trial was co-led by Jeffrey Weinberg, MD, professor of Neurosurgery, and Thomas H. Beckham, MD, PhD, assistant professor of CNS Radiation Oncology at The University of Texas MD Anderson Cancer Center."Surgery is the primary treatment for operable brain
More news about: GT Medical Technologies
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
when they are more treatable and potentially curable, so that patients have the chance of living longer and more productive lives," said Josh Ofman, MD, MSHS, President and CEO-Elect at GRAIL. "The NHS-Galleri trial provides a wealth of data that support the use of the Galleri test to reduce the burden
More news about: GRAIL, Inc.
May 30, 2026, 04:14 ET Replenish Nutrients: Market Has Yet to Price in the H2 2026 Capacity and Licensing Inflection
per month capacity by Q3 2026, with the load-out tower nearing completion and 24-hour production crews being staffed, as disclosed in the Q1 2026 MD&A. Alongside this, Replenish has disclosed a new partnership with the Beiseker Hutterite colony — a development that, to our knowledge, had not been
More news about: Replenish Nutrients
May 29, 2026, 18:31 ET MD Hyperbaric expands national footprint to Texas, Nevada and New York
www.mdhyperbaric.com.About MD Hyperbaric MD Hyperbaric is a leading provider of medical-grade hyperbaric oxygen therapy (HBOT), delivering safe, effective treatment through personalized protocols designed by clinical teams. Founded in 2021 by Dr. Martin O'Malley, MD Hyperbaric utilizes FDA-cleared,
More news about: MD Hyperbaric
May 29, 2026, 17:48 ET Researchers From NYU Langone Health's Perlmutter Cancer Center Present Latest Findings at 2026 ASCO Annual Meeting
"Our dedication to leading-edge research ensures that patients receive the most current and effective care available," said Anirban Maitra, MD, director of Perlmutter Cancer Center. "By integrating personalized patient care with the expertise of our multidisciplinary teams, groundbreaking research,
More news about: NYU Langone Health System
May 29, 2026, 17:32 ET Harford Mutual Insurance Group Announces Board Reelections Following Annual Meeting
BEL AIR, Md., May 29, 2026 /PRNewswire/ -- Harford Mutual Insurance Group (HMIG) announced the reelection of four board members, approved during the Annual Meeting of Policyholders on May 20, 2026.
More news about: Harford Mutual Insurance Group
May 29, 2026, 16:47 ET Celebrate World Digestive Health Day With Gundry MD Bio Complete 3, A Unique Supplement That Is Redefining Gut Health Support
concerns or digestive conditions.Gundry MD Bio Complete 3 Frequently Asked Questions (FAQs)Is Gundry MD Bio Complete 3 Suitable for People Following a Lectin-Free or Plant-Based Diet?Yes. Gundry MD Bio Complete 3 is designed to align with lectin-free
More news about: Gundry MD
May 29, 2026, 14:13 ET Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants
long-term health."Better hearing is about more than sound, it's about supporting a person's overall health throughout their life," Dr. Brian Kaplan MD, FACS, Cochlear Senior Vice President, Global Clinical Strategy & Innovation said."When choosing a cochlear implant, it's important to consider
More news about: Cochlear North America
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
fr. Accessed May 2026. 23 Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission,
More news about: Johnson & Johnson
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
altération de la voie PI3K (ER+/HER2), en particulier en cas de coexistence de mutations des gènes ESR1 et PIK3CA », a déclaré Sara Tolaney, MD, MPH, responsable de la division d'oncologie mammaire du Dana-Farber Cancer Institute. « Ces données préliminaires encourageantes suggèrent la possibilité
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:13 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 ER+, HER2- 전이성 유방암(mBC) 환자를 대상으로 엘라세스트란트와 카피바서팁 병용요법을 평가한 1b/2상 ELEVATE 시험 신규 데이터 발표
10.9개월이었다. 또한 이러한 초기 결과는 병용요법이 각 표적 요법과 표준 치료 내분비 요법의 알려진 안전성 프로필과 일치한다는 점을 보여준다.다나파버 암연구소(Dana-Farber Cancer Institute) 유방종양학부장인 사라 톨라니(Sara Tolaney, MD, MPH) 박사는 "엘라세스트란트와 카피바서팁 병용요법은 ER+/HER2- PI3K 경로 변이 전이성 유방암 환자, 특히 ESR1 및 PIK3CA 공존 돌연변이가 있는 환자의 미충족 수요를 해결하도록 설계됐다"며 "이러한 고무적인 예비 데이터는 병용 요법이 ESR1
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 08:52 ET Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
limited treatment options, particularly in the first-line setting," said John Heymach, M.D., Ph.D, Chair of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, and presenting author. "The WU-KONG28 trial marks a clinical turning point. The data demonstrate that a single-agent targeted
More news about: Dizal Pharmaceutical
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
regimens have demonstrated a favorable efficacy and safety profile in the first-line setting for chronic lymphocytic leukemia," said Svetlana Kobina, MD, PhD, vice president, global medical affairs, oncology, AbbVie. "The inclusion of additional fixed-duration, chemotherapy-free, oral VENCLYXTO combinations
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
regimens have demonstrated a favorable efficacy and safety profile in the first-line setting for chronic lymphocytic leukemia," said Svetlana Kobina, MD, PhD, vice president, global medical affairs, oncology, AbbVie. "The inclusion of additional fixed-duration, chemotherapy-free, oral VENCLYXTO combinations
More news about: AbbVie
May 29, 2026, 07:00 ET Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
study aims to evaluate a practical approach that can strengthen genetic risk identification for patients and their families," noted Frank A. Sinicrope, MD, from the Mayo Clinic and Heather Hampel, MS, CGC, from City of Hope, who are co-lead investigators for the trial. "The findings have the potential to
More news about: Labcorp
May 29, 2026, 06:10 ET Allegheny Health Network's Allegheny General Hospital Once Again Earns Elite 3‑Star Rating for Cardiac Surgery Excellence, Placing it Among the Top Programs Nationwide
Imran Qadeer, MD, president, AGH. "This distinction reinforces AHN Allegheny General Hospital's role as a national leader in complex cardiac care and underscores our
More news about: Allegheny Health Network
May 29, 2026, 03:27 ET Bajaj Finserv launches 'Finserv Intelligence' to back India's AI & deep-tech research and innovation; Partners IIT Bombay
scalability potential across AI, cybersecurity, quantum technologies, fintech, and consumer technology platforms.Rajeev Jain, Vice Chairman & MD, Bajaj Finance, said, "Finserv Intelligence offers founders something fundamentally different from capital alone. Startups will plug directly into Bajaj
More news about: Bajaj Finserv
May 28, 2026, 19:00 ET Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry
More news about: Innovent Biologics
May 28, 2026, 16:21 ET The Inner Circle acknowledges, Deryk G. Jones, MD, FAAOS, FAOA as a Pinnacle Lifetime Member
multimedia:https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-deryk-g-jones-md-faaos-faoa-as-a-pinnacle-lifetime-member-302784878.htmlSOURCE
More news about: The Inner Circle